Serum anti‐Spike immunoglobulin G levels in random blood donors in Italy: High‐titre convalescent plasma is easier than ever to procure
- 25 July 2023
- journal article
- research article
- Published by Wiley in Vox Sanguinis
- Vol. 118 (9) , 794-797
Abstract
Background and Objectives: COVID‐19 convalescent plasma (CCP) has retained potency and clinical efficacy against SARS‐CoV‐2 and is currently of utmost value for seronegative immunocompromised patients. Since most of the effect is due to the vaccine boost of infection‐elicited antibodies, there is a theoretical concern that the frequency of suitable donors is declining.Materials and Methods: In this single‐institution serosurvey, we screened 599 consecutive donors attending our area in two different seasons (300 in November 2022 and 299 in February 2023) using the Abbott Alinity® anti‐Spike immunoglobulin G assay.Results: More than 80% of random donors qualify according to the FDA criteria for high‐titre CCP (>4350 AU/mL), with a stable trend.Conclusion: Despite reduced anti‐Spike vaccine boost deployment in the general population, we have shown here that high‐titre CCP units are easier than ever to procure. This finding also has implications for the derivation of standard immunoglobulins, which are finally approaching the potency of hyperimmune serum and could soon represent an alternative to CCP.Keywords
This publication has 11 references indexed in Scilit:
- Analysis of SARS-CoV-2 mutations associated with resistance to therapeutic monoclonal antibodies that emerge after treatmentmedRxiv, 2023
- Plasma after both SARS-CoV-2 boosted vaccination and COVID-19 potently neutralizes BQ.1.1 and XBB.1bioRxiv, 2022
- Prevalence of Contraindications to Nirmatrelvir-Ritonavir Among Hospitalized Patients With COVID-19 at Risk for Progression to Severe DiseaseJAMA Network Open, 2022
- Analysis of anti-SARS-CoV-2 Omicron-neutralizing antibody titers in different vaccinated and unvaccinated convalescent plasma sourcesNature Communications, 2022
- COVID-19 Convalescent Plasma and Clinical Trials: Understanding Conflicting OutcomesClinical Microbiology Reviews, 2022
- A Critical Analysis of the Use of Cilgavimab plus Tixagevimab Monoclonal Antibody Cocktail (Evusheld™) for COVID-19 Prophylaxis and TreatmentViruses, 2022
- Passive immunotherapies for COVID‐19: The subtle line between standard and hyperimmune immunoglobulins is getting invisibleReviews in Medical Virology, 2022
- Hyperimmune immunoglobulin for hospitalised patients with COVID-19 (ITAC): a double-blind, placebo-controlled, phase 3, randomised trialThe Lancet, 2022
- Access to and safety of COVID-19 convalescent plasma in the United States Expanded Access Program: A national registry studyPLOS Medicine, 2021
- Compassionate use of convalescent plasma for treatment of moderate and severe pneumonia in COVID-19 patients and association with IgG antibody levels in donated plasmaeClinicalMedicine, 2020